1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Cipla And Alvotech Prime Emerging Markets Push With Adalimumab Deal

 
• By Anju Ghangurde
  
Generate a summary of this article
Listen to this article
Beta

Cipla has firmed up a commercialization deal with Alvotech for the Icelandic developer’s high-concentration version of AbbVie’s Humira, continuing to use the licensing approach to expand its biosimilar franchise in emerging markets.

Business Puzzle

Cipla Ltd. continues to build its portfolio of biosimilars via in-licensing after having decided to reposition its biotech business from a capital allocation standpoint and cut back on “organic” development and manufacturing. The Indian company has now struck a commercialization deal with Alvotech for its late stage biosimilar version of AbbVie Inc.’s Humira (adalimumab), the top-selling medicine worldwide.

The deal, routed through Cipla Gulf FZ LLC, a wholly owned arm of Cipla, will see the Indian group commercialize...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.